On July 27, 2022 AbCellera (Nasdaq: ABCL) and Versant Ventures reported a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs (Press release, AbCellera, JUL 27, 2022, View Source [SID1234617005]). Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive research payments from the companies and will be eligible to receive downstream clinical and commercial milestone payments plus royalties on net sales of products. Further terms are not disclosed.

"In recent years we have made a series of investments into the next generation of therapeutic antibodies," said Markus Enzelberger, Ph.D., a partner at Versant. "We are seeing a wave of innovation in the antibody space that is allowing us to add novel functionalities to these molecules. Our partnership with AbCellera will further enable our portfolio companies to pursue these important biologic medicines."

"AbCellera’s discovery technology provides a complete solution for antibody therapeutics that unlocks new opportunities and levels the playing field for smaller companies, allowing them to advance programs faster, more efficiently and with a competitive advantage," said Carl Hansen, Ph.D., CEO and President of AbCellera. "We are excited to deepen our relationship with the Versant team and look forward to helping them continue a strong track record of bringing together breakthrough science, experienced teams, and capital to create bold new biotech companies."

Previously, Versant and AbCellera partnered in separate multi-target deals to enable three of the firm’s stealth-stage companies with new approaches to optimize and expand antibody therapies. These include antibody-focused newcos in the fields of immunology and oncology based in Canada, the U.S. and Europe.

On July 27, 2022 EVERSANA reported to be a Global Sponsor at this year’s Pharma Japan 2022 hosted by Reuters, taking place on 28-29 September (Press release, EVERSANA, JUL 27, 2022, View Source [SID1234617004]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pharma has entered a new world, where scientific innovation is no longer enough to be successful. This, coupled with looming deregulation and an influx of innovative treatments, means that the time is now for you to put your strategy for the future into action. It’s time to go beyond the medicine and focus on patient value.

EVERSANA is present at Pharma Japan and committed to providing insights and support to our clients during this transformative time in our industry.

Join EVERSANA’s Rob Arnold, Executive Vice President for APAC, on September 28 at 9:10-9:30 JST as he presents the session "Beyond Fortress Japan." In this session, Rob will discuss how Japanese companies can no longer rely on the model of selling in Japan and out-licensing elsewhere. They need to enter at least EU, US and China and they need to do it soon. However, this is fraught with risk and requires alignment and tenacity. EVERSANA will share our thoughts on the emerging entry models based on our client support perspective.

Talk with our business experts to learn more about how our global commercial solutions provide you with the right strategies and tools to help accelerate your speed to market. Click the button below to schedule a meeting. Look for an EVERSANA team member live on the conference networking platform.

On July 27, 2022 EVERSANA reported at 7th Annual CAR-TCR Summit (Press release, EVERSANA, JUL 27, 2022, View Source [SID1234617003]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As the industry focuses more on specialty therapies, it is imperative that manufacturers move to a patient-centered care model that delivers value enabled by innovative technologies and measured by actionable data.

As the only go-to complete commercialization expert in the industry, EVERSANATM brings together strategy, patient recruitment for clinical trials, HCPs and patient engagement across the patient journey, and warehousing and logistics to support complex transportation needs.

Join EVERSANA’s Brian Urban, Senior Implementation Director and Seth Gordon, General Manager, EVERSANA INTOUCH Engage during their September 21st plenary presentation, "Incorporating Patient Insights & Engagement for Clinical & Commercial Success," at 8:40 am EST.

To schedule a meeting with our cell and gene therapy experts at the CAR-TCR Summit, click here.

On July 27, 2022 EVERSANA reported to be a Summit Partner at this year’s DTx East Summit taking place September 27-29 in Boston (Press release, EVERSANA, JUL 27, 2022, View Source [SID1234617002]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Join EVERSANA and other leaders in the industry as we advance the conversation on:

Commercializing digital therapeutics by navigating the local regulatory pathways to approval
Advancing the adoption of companion apps
Securing broad payer coverage and reimbursement for digital therapies
The DTx summits are the premier event series for senior executives from DTx companies, and pharma, investors, HCPs, payers and more. DTx East 2021 is the ninth summit in the DTx series. The industry leaders and most exciting newcomers will be in attendance across an in-person and online event.

On July 27, 2022 Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") reported the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA) (Press release, Dr Reddy’s, JUL 27, 2022, View Source [SID1234617001]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health*.

Dr. Reddy’s Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.

Velcade is a trademark of Takeda Pharmaceuticals U.S.A., Inc.

*IQVIA Retail and Non-Retail MAT May 2022

RDY-0722-430